Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 117,076,648
  • Shares Outstanding, K 254,034
  • Annual Sales, $ 12,001 M
  • Annual Income, $ 3,953 M
  • EBIT $ 4,173 M
  • EBITDA $ 4,383 M
  • 60-Month Beta 0.31
  • Price/Sales 9.67
  • Price/Cash Flow 25.98
  • Price/Book 6.21

Options Overview Details

View History
  • Implied Volatility 30.51% (-14.43%)
  • Historical Volatility 39.01%
  • IV Percentile 56%
  • IV Rank 33.59%
  • IV High 47.19% on 04/08/25
  • IV Low 22.08% on 08/27/25
  • Expected Move (DTE 3) 13.68 (2.75%)
  • Put/Call Vol Ratio 0.88
  • Today's Volume 8,702
  • Volume Avg (30-Day) 4,777
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 50,592
  • Open Int (30-Day) 47,776
  • Expected Range 483.68 to 511.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.91
  • Number of Estimates 7
  • High Estimate 4.37
  • Low Estimate 3.51
  • Prior Year 3.55
  • Growth Rate Est. (year over year) +10.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
450.67 +10.63%
on 03/06/26
507.50 -1.76%
on 03/10/26
+35.10 (+7.57%)
since 02/10/26
3-Month
429.00 +16.22%
on 01/20/26
507.50 -1.76%
on 03/10/26
+53.93 (+12.13%)
since 12/10/25
52-Week
362.50 +37.54%
on 08/11/25
519.68 -4.06%
on 03/14/25
-1.43 (-0.29%)
since 03/10/25

Most Recent Stories

More News
US stocks hold steadier as Wall Street waits for the next signal on how long war with Iran may last

The U.S. stock market is holding steadier as Wall Street waits for the next signal on when the war with Iran may end

$SPX : 6,779.17 (-0.25%)
VRTX : 499.08 (+8.29%)
$DOWI : 47,706.51 (-0.07%)
KSS : 14.58 (-1.49%)
$IUXX : 24,937.09 (-0.12%)
Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

Why Vertex Pharmaceuticals (VRTX) Stock Is Up Today

VRTX : 499.08 (+8.29%)
Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved...

VRTX : 499.08 (+8.29%)
Vertex to Participate in Upcoming March Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and...

VRTX : 499.08 (+8.29%)
Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the...

VRTX : 499.08 (+8.29%)
Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

VRTX : 499.08 (+8.29%)
$DOWI : 47,706.51 (-0.07%)
BIIB : 188.57 (+0.18%)
2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

2 Nasdaq 100 Stocks Worth Your Attention and 1 We Question

NFLX : 96.94 (-1.40%)
VRTX : 499.08 (+8.29%)
GILD : 148.44 (+1.23%)
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

CRSP : 52.16 (-11.26%)
MS : 160.73 (+0.17%)
VRTX : 499.08 (+8.29%)
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call

5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call

VRTX : 499.08 (+8.29%)
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down

SOLV : 67.62 (-1.43%)
VRTX : 499.08 (+8.29%)
VMC : 271.98 (-0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which...

See More

Key Turning Points

3rd Resistance Point 474.97
2nd Resistance Point 468.12
1st Resistance Point 464.49
Last Price 499.08
1st Support Level 454.01
2nd Support Level 447.16
3rd Support Level 443.53

See More

52-Week High 519.68
Last Price 499.08
Fibonacci 61.8% 459.64
Fibonacci 50% 441.09
Fibonacci 38.2% 422.54
52-Week Low 362.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar